Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT

作者：Rongtao Xue, Min Dai, Erlie Jiang, Xueying Ou, Fen Huang, Zhiping Fan, Na Xu, Chen‐Hua Yan, Danian Nie, Xinquan Liang, Hong Chen, Jieyu Ye, Ling Jiang, Hui Liu, Hua Jin, Ren Lin, Yu Zhang, Jing Sun, Mingzhe Han, Qifa Liu, Yu Wang, Li Xuan · 发表于：Blood Cancer Journal · 年份：2025 · DOI：10.1038/s41408-025-01233-9 · 被引用次数：5 · 研究领域：Acute Myeloid Leukemia Research、Chronic Myeloid Leukemia Treatments、Myeloproliferative Neoplasms: Diagnosis and Treatment

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative therapy for patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia evolving from MDS (sAML) [ 1 ]. Multiple factors are reported to influence the prognosis of patients with MDS and sAML undergoing allo-HSCT, including prognostic stratification, disease status, conditioning regimen and pre-transplant therapy [ 2 , 3 ]. Our randomized controlled trial (RCT) has shown that granulocyte-colony stimulating factor, decitabine, busulfan and cyclophosphamide (G-DAC-BuCy) conditioning is a better choice than busulfan and cyclophosphamide (BuCy) conditioning for patients with MDS-refractory anemia with excess blasts (RAEB) or sAML undergoing allo-HSCT [ 4 ].